John Sellers

Cooley advised Candid Therapeutics, a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases, on its $370 million debut capital raise and three-way merger with Vignette Bio and TRC 2004.

Cooley advised Arsenal Biosciences (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced chimeric antigen receptor T-cell (CAR-T) therapies for solid tumors, on the close of its oversubscribed $325 million Series C financing round.

Cooley advised Grafana Labs, the company behind ubiquitous, open and composable operational dashboards, on the successful completion of its approximately $270 million primary and secondary transaction.

Cooley advised Abnormal Security, the leader in AI-native human behavior security, on its $250 million Series D financing at a $5.1 billion valuation.

Cooley advised Outpace Bio, a cell therapy company using unrivaled artificial intelligence-powered protein design to program immune cells for improved function inside patients battling solid tumors, on its $144 million oversubscribed Series B financing.